Podcast: Treating Autoimmune Neuropsychiatric Diseases

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

In Vivo Podcast

La Jolla, California-based Arialys Therapeutics is developing therapeutics to treat neuropsychiatric conditions with an autoimmune etiology. According to CEO Peter Flynn, these may not be as uncommon as we might think.

Peter Flynn, Arialys
Peter Flynn, Arialys (Arialys)

As he notes in this episode of the In Vivo podcast, there are indications that subsets of patients with schizophrenia, schizoaffective disorder, dementia, psychosis and autism, as well as other conditions, have high levels of auto-antibodies to the NMDA receptor.

Whether the antibodies are causing the symptoms remains to be established, as the science of autoimmune neuropsychiatry is relatively new.

For now, however, the startup is focusing on developing its lead asset, ART5803, a monoclonal antibody for the treatment of anti-NMDA receptor encephalitis.

Listen to the podcast as Flynn talks about his own 20-plus years of executive biotech leadership experience at Artiva Biotherapeutics, Orexigen and Fate Therapeutics, describes what is known about autoimmune neuropsychiatric disorders, describes the journey of patients with anti-NMDA encephalitis and touches on the company’s commercialization and growth strategy.

Timestamps:

Intro

1:00 - Flynn’s career trajectory

2:35 - Origins of Arialys, including the purchase of its lead asset from Astellas

4:00 - The evolving science of autoimmune neuropsychiatric conditions and anti-NMDA receptor encephalitis

8:45 - Testing for auto-antibodies to the central nervous system exist but are not sensitive enough and require spinal tap

11:25 - Arialys' lead asset, ART5803, for anti-NMDA receptor encephalitis

15:40 - The current standard of care and the patient journey

19:35 - Increasing physician awareness of the disease

21:00 - Arialys' commercialization and growth strategy

More from Podcasts

Faron CEO Discusses Potential “Game Changer” For High-Risk MDS Patient Population

 

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.

Podcast: How Fauna Bio Gleans Therapeutic Insights From Animals

 
• By 

In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.

Podcast: Pre-JPM Biotech Dealmaking Panel

 
• By 

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

Podcast: The Future Of Immunotherapy

 
• By 

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

More from Innovation

BioBytes: AI-Related Deals In Q4 ‘24

 
• By 

The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.

Podcast: How Fauna Bio Gleans Therapeutic Insights From Animals

 
• By 

In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.

Taming Dragons: AI Innovation For Blood Cancer Drug Discovery

 
• By 

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.